Menu Search
Equities

Biohit Oyj

BIOBV:HEX

Biohit Oyj

Actions
Health CareMedical Equipment and Services
  • Price (EUR)2.30
  • Today's Change-0.02 / -0.86%
  • Shares traded6.37k
  • 1 Year change+18.86%
  • Beta0.6453
Data delayed at least 15 minutes, as of Nov 21 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Biohit Oyj grew revenues 19.40% from 10.95m to 13.08m while net income improved 207.99% from 601.00k to 1.85m.
Gross margin61.28%
Net profit margin12.53%
Operating margin11.63%
Return on assets13.12%
Return on equity16.68%
Return on investment16.92%
More ▼

Cash flow in EURView more

In 2023, Biohit Oyj increased its cash reserves by 42.65%, or 905.00k. The company earned 902.00k from its operations for a Cash Flow Margin of 6.90%. In addition the company generated 192.00k cash from investing, though they paid out 199.00k more in financing than they received.
Cash flow per share0.1398
Price/Cash flow per share13.39
Book value per share0.7118
Tangible book value per share0.6854
More ▼

Balance sheet in EURView more

Biohit Oyj has a Debt to Total Capital ratio of 6.09%, a higher figure than the previous year's 5.56%.
Current ratio4.30
Quick ratio3.93
Total debt/total equity0.0648
Total debt/total capital0.0609
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.